DekaBank Deutsche Girozentrale
MRTX

DekaBank Deutsche Girozentrale’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$1.16M – 1533
2023
Q4 		$1.16M Hold
20,000
– – ﹤0.01% 873
2023
Q3 		$898K Hold
20,000
– – ﹤0.01% 897
2023
Q2 		$723K Hold
20,000
– – ﹤0.01% 946
2023
Q1 		$726K Hold
20,000
– – ﹤0.01% 942
2022
Q4 		$845K Sell
20,000
-17,140
-46% -$1.11M ﹤0.01% 922
2022
Q3 		$2.56M Hold
37,140
– – 0.01% 656
2022
Q2 		$2.46M Sell
37,140
-1,750
-4% -$111K 0.01% 680
2022
Q1 		$3.28M Sell
38,890
-600
-2% -$61.4K 0.01% 647
2021
Q4 		$5.68M Buy
39,490
+5,300
+16% +$823K 0.01% 534
2021
Q3 		$5.94M Hold
34,190
– – 0.02% 494
2021
Q2 		$5.48M Hold
34,190
– – 0.02% 502
2021
Q1 		$5.64M Buy
34,190
+11,600
+51% +$2.3M 0.02% 450
2020
Q4 		$4.96M Sell
22,590
-4,960
-18% -$1.07M 0.02% 458
2020
Q3 		$4.54M Buy
27,550
+14,150
+106% +$1.94M 0.02% 428
2020
Q2 		$1.53M Buy
13,400
+4,625
+53% +$449K 0.01% 556
2020
Q1 		$722K Buy
+8,775
New +$787K 0.01% 680

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

DekaBank Deutsche Girozentrale's MRTX Position: Q1 2024 in Review

DekaBank Deutsche Girozentrale sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 20,000 shares — an estimated $1.16M sold.

DekaBank Deutsche Girozentrale first reported a position in MRTX in Q1 2020 and held it in 16 quarters. The position peaked at $5.94M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • DekaBank Deutsche Girozentrale reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 20,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.16M.
  • DekaBank Deutsche Girozentrale first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 16 quarters.
  • DekaBank Deutsche Girozentrale's Mirati Therapeutics, Inc. Common Stock position peaked at $5.94M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2024, filed 24 Apr 2024.